Prometic’s Pulmonary Fibrosis Therapy PBI-4050 Earns FDA Fast Track Status
Idiopathic Pulmonary Fibrosis
The U.S. Food and Drug and Drug Administration has awarded Fast Track status to PBI-4050, Prometic Life Sciences‘ treatment for lung scarring in idiopathic pulmonary fibrosis. The Fast Track designation ... Read more